November 16, 2022, Olathe, KS – Ronawk, the new biotech and biofabrication company powered by the Bio-Block™ platform, today shared highlights of new data published in the October issue of Regenerative Medicine. The article entitled “Novel Hydrogel System Eliminates and Improves Retainment of Non-Senescent Mesenchymal Stem Cell Populations” demonstrates the significant impact of Ronawk’s hydrogel Bio-Block™ system on the cell culture process and the ability to remove the need for subculture from the process. [Read more…]
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA
First entry to clinical trial of exosome for atopic dermatitis and the first exosome-based therapeutics in US clinical trial among Korean companies
SEOUL, South Korea I November 2, 2022 – The US FDA granted the initiation of the phase 1 clinical trial of ‘BRE-AD01’, an exosome- based therapy for atopic dermatitis. ‘BRE-AD01’ is being developed by Brexogen with its own exosome-platform technology. It is the first phase 1 clinical trial of therapeutic exosome for atopic dermatitis in major countries. This IND clearance is very meaningful in that patients with atopic dermatitis can benefit from receiving better treatment with ‘BRE-AD01’, which is armed with multiple mode of action. [Read more…]
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
SAN DIEGO, California, Nov. 01, 2022 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The MD Anderson Cancer Center (“MD Anderson”). [Read more…]
Resolution Therapeutics and CCRM to develop and scale up manufacturing for iPSC-derived macrophage cell therapies
London, UK and Toronto, Canada 7 November, 2022 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, CCRM, one of the leading companies developing and commercializing regenerative medicine-based technologies and cell and gene therapies, and OmniaBio Inc., CCRM’s subsidiary, today announced a research collaboration to develop and scale up a manufacturing platform for Resolution’s off-the-shelf iPSC-derived macrophage cell therapies. [Read more…]
Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development
San Francisco, CA, October 19, 2022 – Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories:
- Tempo-iBMEC™ – Human iPSC-derived Brain Microvascular Endothelial Cells
- Tempo-iPeri™ – Human iPSC-derived Pericytes
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 118
- Next Page »